Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Newly arrived migrant

Infectious diseases · Prevention, screening, pregnancy · updated 2026-10-29

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: A flow, not a prevalence: 345 587 first residence permits issued in France in 2024 to third-country nationals (338 877 in 2023), according to Eurostat [1]. Permits valid for at least 3 months, excluding European Union citizens; they do not count asylum seekers without a permit, nor people without a permit.

Adult

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Child

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Sources (9)
  1. Eurostat. First permits issued for family reasons, education reasons, remunerated activities reasons, and other reasons by reason, length of validity and citizenship (migr_resfirst), France, 2022-2024. Données extraites par l'interface de diffusion d'Eurostat, consulté le 24/10/2026 (mise à jour des données du 22/10/2026).
  2. SPILF, SFP, SFLS. Bilan de santé à réaliser chez toute personne migrante primo-arrivante (adulte et enfant). Recommandation, juin 2024.
  3. European Centre for Disease Prevention and Control. Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA. Stockholm : ECDC, décembre 2018.
  4. Office for Health Improvement and Disparities, UK Health Security Agency. Migrant health guide (gov.uk) : pages « Assessing new patients from overseas » (mise à jour du 2 août 2021), « HIV » (31 mars 2025), « Hepatitis B » et « Hepatitis C » (8 avril 2026), « Helminth infections » (31 mars 2025), « Tuberculosis (TB) » (31 mars 2025), « Non-infectious environmental hazards » (31 mars 2025).
  5. US Preventive Services Task Force. Human Immunodeficiency Virus (HIV) Infection: Screening. Final Recommendation Statement, 11 juin 2019 (grade A).
  6. US Preventive Services Task Force. Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323(10):970-975.
  7. US Preventive Services Task Force. Hepatitis B Virus Infection in Adolescents and Adults: Screening. Final Recommendation Statement, 15 décembre 2020 (grade B).
  8. US Preventive Services Task Force. Latent Tuberculosis Infection in Adults: Screening. Final Recommendation Statement, 2 mai 2023 (grade B).
  9. National Institute for Health and Care Excellence. Tuberculosis. NICE guideline NG33, publiée le 13 janvier 2016, dernière mise à jour le 16 février 2024.